



Oligomerix Presents Data on Lead Program at Clinical Trials on Alzheimer's Disease (CTAD) Conference and Society for Neuroscience Meeting

-- Phase 1 trial for oral, small molecule therapeutic targeting tau planned to begin 2Q22 --

WHITE PLAINS, NY (November 09, 2021) -- Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer's and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the [14th Annual Clinical Trials on Alzheimer's Disease](#) (CTAD) conference and at the Society for Neuroscience's (SfN) 50th annual meeting [Neuroscience 2021](#).

A study was conducted in the tau P301L JNPL3 mouse model for tau aggregation and motor impairment that was aged prior to treatment in order to study the therapeutic effect of OLX-07010. Statistically significant results showed that treatment prevented further accumulation of tau aggregates and overall levels of tau in the mice over 5 months of treatment administered in the feed compared to control animals. In parallel, there was improved motor function in the treated mice compared to the baseline and vehicle control groups supporting the therapeutic efficacy of OLX-07010.

"As an oral small molecule, our lead program is a highly differentiated approach that targets tau self-association, the beginning stages of the tau aggregation cascade, for the treatment of neurodegenerative diseases. These results are consistent with our proposed model that inhibition of tau self-association leads to the reduction of the large insoluble tau aggregates and the overall levels of tau," said James Moe, Ph.D., MBA, President and CEO of Oligomerix.

Information for both conferences can be found below.

Late-breaking CTAD virtual oral presentation

"Oral treatment with OLX-07010, a small molecule inhibitor of tau self-association, reduced tau aggregation to baseline in a therapeutic study of aged tau P301L JNPL3 mice."

SfN poster presentation

"Reduction of tau to baseline levels and rescue of motor impairment in a therapeutic study in aged JNPL3 mice treated with small molecule OLX-07010 targeting tau self-association."

"These exciting results provides further confidence in the Oligomerix approach as we prepare to enter clinical testing next year," said Bill Erhardt, M.D., Chief Medical Officer of Oligomerix. "By year end, Oligomerix will complete all necessary IND enabling studies and we will submit our IND to FDA during 1Q22. We anticipate the start of first-in-human studies in 2Q22 with the goal of testing the safety and efficacy of OLX-07010 for Alzheimer's disease and rare tauopathies. This represents a major milestone achievement for Oligomerix."

-more-

Oligomerix Presents Data on Lead Program at Clinical Trials on Alzheimer's Disease (CTAD) Conference and Society for Neuroscience Meeting
November 9, 2021

About Oligomerix's Lead Program

Oligomerix's lead candidate, OLX-07010 is an oral, small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade, a process thought to be important in the development of Alzheimer's disease and other neurodegenerative disorders. Our lead compound, OLX-07010, has demonstrated efficacy in several animal models of neurodegeneration and, upon completion of its preclinical program, will start Phase 1 clinical studies in the first half of 2022.

About Oligomerix, Inc.

Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer's disease.

With a focus on oral, small molecule, tau inhibitors that block tau self-association in the early steps of the tau aggregation cascade, Oligomerix seeks to develop therapies for Alzheimer's disease and other dementias that are easy to administer and cost effective and could complement both tau and beta-amyloid antibody treatment.

Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine. Follow Oligomerix on [Twitter](#) and [LinkedIn](#).

Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit our new website at <https://oligomerix.com/>.

Company Contacts

Jack Pasini
Chief Commercial Officer
917-912-4088
ipasini@oligomerix.com

James Moe, Ph.D., MBA
President and CEO
212-568-0365 Ext. 104
jmoe@oligomerix.com

Media Contact

Michelle Linn
Bioscribe
774-696-3803
michelle@bioscribe.com